Organic compounds
US10077267B2 · kind B2 · utility
55Cited by
82References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 3, 2015 |
| Grant date | Sep 18, 2018 |
| Priority date | — |
| Expiry date | Apr 3, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.